Jun 03, 2021 / 06:30PM GMT
Brandon Couillard - Jefferies LLC, Research Division - Equity Analyst
All right. We'll go ahead and get started. Thanks, everyone, for joining us. Welcome to the Jefferies 2021 Global Healthcare Conference. I'm Brandon Couillard. I cover the Life Science Tools and Diagnostics sector here at the firm. It's my great pleasure to have Repligen with us back at the conference this year. Joining us for this conversation this afternoon, CEO, Tony Hunt; CFO, Jon Snodgres. Gentlemen, thanks for being here.
Anthony J. Hunt - Repligen Corporation - CEO, President & Director
Thanks, Brandon.
Questions and Answers:
Brandon Couillard - Jefferies LLC, Research Division - Equity AnalystTony, to jump in and kick-off. I think one of the certainly biggest debates and conversations among investors right now is just kind of what does the vaccine-related revenue picture look like second half of this year, but also into '22? Just near term, you did $35 million in the first quarter, kind of pointed to about $150 million at the